Galena. The company will be renamed SELLAS Life Science Group Inc. SELLAS has a lead asset called galinpepimut-S (GPS), which is a Wilm's Tumor 1 (WT1)-targeting peptide-based immunotherapeutic. Roughly 4.6 million shares were traded yesterday compared to just an average of around 500,000 shares.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.